Title
Association of Cohort and Individual Substance Use with Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission from Disorder: Findings from the World Mental Health Surveys
Date Issued
01 July 2019
Access level
open access
Resource Type
journal article
Author(s)
Degenhardt L.
Bharat C.
Glantz M.D.
Sampson N.A.
Al-Hamzawi A.
Alonso J.
Andrade L.H.
Bunting B.
Cia A.
De Girolamo G.
De Jonge P.
Demyttenaere K.
Gureje O.
Haro J.M.
Harris M.G.
He Y.
Hinkov H.
Karam A.N.
Karam E.G.
Kiejna A.
Kovess-Masfety V.
Lasebikan V.
Lee S.
Levinson D.
Medina-Mora M.E.
Mneimneh Z.
Navarro-Mateu F.
Posada-Villa J.
Scott K.
Stein D.J.
Tachimori H.
Tintle N.
Torres Y.
Kessler R.C.
Publisher(s)
American Medical Association
Abstract
Importance: Limited empirical research has examined the extent to which cohort-level prevalence of substance use is associated with the onset of drug use and transitioning into greater involvement with drug use. Objective: To use cross-national data to examine time-space variation in cohort-level drug use to assess its associations with onset and transitions across stages of drug use, abuse, dependence, and remission. Design, Setting, and Participants: The World Health Organization World Mental Health Surveys carried out cross-sectional general population surveys in 25 countries using a consistent research protocol and assessment instrument. Adults from representative household samples were interviewed face-to-face in the community in relation to drug use disorders. The surveys were conducted between 2001 and 2015. Data analysis was performed from July 2017 to July 2018. Main Outcomes and Measures: Data on timing of onset of lifetime drug use, DSM-IV drug use disorders, and remission from these disorders was assessed using the Composite International Diagnostic Interview. Associations of cohort-level alcohol prevalence and drug use prevalence were examined as factors associated with these transitions. Results: Among the 90027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1] years), 1 in 4 (24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of prescription drugs at some point in their lifetime, but with substantial time-space variation in this prevalence. Among users, 9.1% (SE, 0.2%) met lifetime criteria for abuse, and 5.0% (SE, 0.2%) met criteria for dependence. Individuals who used 2 or more drugs had an increased risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P <.001) and dependence (odds ratio, 5.99 [95% CI, 5.02-7.16]; P <.001) and reduced probability of remission from abuse (odds ratio, 0.86 [95% CI, 0.76-0.98]; P =.02). Birth cohort prevalence of drug use was also significantly associated with both initiation and illicit drug use transitions; for example, after controlling for individuals' experience of substance use and demographics, for each additional 10% of an individual's cohort using alcohol, a person's odds of initiating drug use increased by 28% (odds ratio, 1.28 [95% CI, 1.26-1.31]). Each 10% increase in a cohort's use of drug increased individual risk by 12% (1.12 [95% CI, 1.11-1.14]). Conclusions and Relevance: Birth cohort substance use is associated with drug use involvement beyond the outcomes of individual histories of alcohol and other drug use. This has important implications for understanding pathways into and out of problematic drug use.
Start page
708
End page
720
Volume
76
Issue
7
Language
English
OCDE Knowledge area
Psicología (incluye relaciones hombre-máquina)
Psiquiatría
Scopus EID
2-s2.0-85062949247
PubMed ID
Source
JAMA Psychiatry
ISSN of the container
2168622X
Sponsor(s)
Reports receiving investigator-initiated untied educational grants for studies of opioid medications in Australia from Indivior, Mundipharma, and Seqirus. Dr Kessler reports receiving support for his epidemiological studies from Sanofi Aventis; serving as a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, and Takeda; serving on an advisory board for the Johnson & Johnson Services Inc Lake Nona Life Project; and being a coowner of DataStat Inc, a market research firm that carries out healthcare research. Dr Demyttenaere reports having served on advisory boards for Boehringer Ingelheim, Eli Lilly, Lundbeck, Johnson & Johnson, Livanova, and Servier, and receiving research grants from Eli Lilly, Fonds Gavoor Geluk, and Fonds voor Wetenschappelijk Onderzoek Vlaanderen. Dr Stein has received research grants and/or consultancy honoraria from AMBRF/Foundation for Alcohol Research, Biocodex, Cipla, Lundbeck, National Responsible Gambling Foundation, Novartis, Servier, and Sun. Dr Tachimori reports grants from the Japan Agency for Medical Research and Development and the Ministry of Health, Labour and Welfare, Japan, during the conduct of the study. No other disclosures were reported.
World Mental Health Survey Initiative is supported by the United States National Institute of Mental Health (grant R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (grants R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (grant FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc, GlaxoSmithKline, and Bristol-Myers Squibb. This work was supported by an Australian National Health and Medical Research Council project grant (1081984). Dr Degenhardt is supported by a National Health and Medical Research Council Senior Principal Research Fellowship (grant 1135991) and the National Institute on Drug Abuse (grant R01 DA044170-02). We thank the staff of the World Mental Health Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. The 2007 Australian National Survey of Mental Health and Wellbeing is funded by the Australian Government Department of Health and Ageing. The Argentina survey (Estudio Argentino de Epidemiología en Salud Mental) was supported by a grant from the Argentinian Ministry of Health (Ministerio de Salud de la Nación). The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation (thematic project grant 03/00204-3). The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Colombian National Study of Mental Health is supported by the Ministry of Social Protection. The Mental Health Study Medellín, Colombia was carried out and supported jointly by the Center for Excellence on Research in Mental Health (at CES University) and the Secretary of Health of Medellín. The European Study of the Epidemiology of Mental Disorders project is funded by the European Commission (contracts QLG5-1999-01042, SANCO 2004123, and EAHC 20081308), the Piedmont Region (Italy), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (grant FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (grant SAF 2000-158-CE), Generalitat de Catalunya (grants 2017 SGR 452 and 2014 SGR 748), Instituto de Salud Carlos III (CIBER grants CB06/02/0046 and RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey and data entry were carried out by the staff of the Iraqi Ministry of Health and Ministry of Planning with direct support from the Iraq Mental Health Survey team, with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund. The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (grants H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, and H25-SEISHIN-IPPAN-006) from the Japan Ministry of Health, Labour and Welfare. The Lebanese Evaluation of the Burden of Ailments and Needs Of the Nation is supported by the Lebanese Ministry of Public Health, the World Health Organization Lebanon, the National Institutes of Health/Fogarty International Center (grant R03 TW006481-01), anonymous private donations to the Institute for Development, Research, Advocacy and Applied Care, Lebanon, and unrestricted grants from Algorithm, AstraZeneca, Benta, Bella Pharma, Eli Lilly, Glaxo Smith Kline, Lundbeck, Novartis, OmniPharma, Pfizer, Phenicia, Servier, and UPO. The Mexican National Comorbidity Survey is supported by The National Institute of Psychiatry Ramon de la Fuente (grant INPRFMDIES 4280) and by the National Council on Science and Technology (grant CONACyT-G30544-H), with supplemental support from the Pan American Health Organization. Te Rau Hinengaro: The New Zealand Mental Health Survey is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Nigerian Survey of Mental Health and Wellbeing is supported by the World Health Organization Geneva, the World Health Organization Nigeria, and the Federal Ministry of Health in Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Polish project Epidemiology of Mental Health and Access to Care –EZOP Project (grant PL 0256) was supported by Iceland, Liechtenstein, and Norway through funding from the European Economic Area Financial Mechanism and the Norwegian Financial Mechanism, and cofinanced by the Polish Ministry of Health. The South Africa Stress and Health Study is supported by the US National Institute of Mental Health (grant R01-MH059575) and National Institute of Drug Abuse, with supplemental funding from the South African Department of Health and the University of Michigan. The Psychiatric Enquiry to General Population in Southeast Spain–Murcia Project has been financed by the Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) and Fundación para la Formación e Investigación Sanitarias of Murcia. The Ukraine Comorbid Mental Disorders during Periods of Social Disruption study is funded by the US National Institute of Mental Health (grant RO1-MH61905). The US National Comorbidity Survey–Replication is supported by the National Institute of Mental Health (grant U01-MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (grant 044708), and the John W Alden Trust. Dr Andrade is supported by the Brazilian Council for Scientific and Technological Development (CNPq Grant 307784/2016-9). Dr Stein is supported by the Medical Research Council of South Africa. Dr Glantz’s role on this study is through his involvement as a Science Officer on National Institute of Mental Health grant U01-MH60220.
Sources of information:
Directorio de Producción Científica
Scopus